Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Journals » Journal of Pain Management » Volume 4 Issue 3 Articles » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Postpartum Hemorrhage and Cesarean Section: Complications of Labor and Delivery
$82.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Bestsellers
01.Targeting TRPV1 for Pain Relief: Should we Quench or Reignite the Fire?
02.Spinal Cord Neural Plasticity in Chronic Pain and its Clinical Implication
03.Plasticity in Chronic Pain Syndromes: The Role of Neuroimaging
Notifications more
NotificationsNotify me of updates to Targeting TRPV1 for Pain Relief: Should we Quench or Reignite the Fire?
Tell A Friend
 
Tell someone you know about this product.
Targeting TRPV1 for Pain Relief: Should we Quench or Reignite the Fire? $45.00
Authors:  Marcello Trevisani and Arpad Szallasi
Abstract:
Preclinical research has recently uncovered new molecular mechanisms underlying the generation and transduction of pain, many of which represent opportunities for pharmacological intervention. Manipulating TRP (Transient Receptor Potential) channels on nociceptive neurons is a particularly attractive strategy in drug development in that it targets the beginning of the pain pathway. The vanilloid (capsaicin) receptor TRPV1 is a multifunctional channel involved in thermosensation (heat) and taste perception (e.g. peppers and vinegar). Importantly, TRPV1 also functions as a molecular integrator for a broad range of seemingly unrelated noxious stimuli. Indeed, TRPV1 is thought to be a major transducer of the thermal hyperalgesia that follows inflammation and/or tissue injury. Desensitization to topical TRPV1 agonists (e.g. capsaicin creams and patches) has been in clinical use for decades to alleviate chronic painful conditions like diabetic neuropathy. Currently, site-specific capsaicin and resiniferatoxin (an ultrapotent capsaicin analogue) injections are being evaluated as “molecular scalpels” to achieve permanent analgesia in cancer patients with chronic, intractable pain. In the last five years, a number of potent, small molecule TRPV1 antagonists have been advanced into clinical trials for the treatment of inflammatory, neuropathic and visceral pain. Some of these compounds have successfully passed Phase 1 safety and tolerability studies in healthy volunteers into Phase 2 studies to access efficacy in patients, whereas others showed worrisome unforeseen adverse effects (most important, hyperthermia and impaired noxious heat sensation placing the patient at risk for scalding injury) in men, prompting their withdrawal from the clinical trials. In this paper, we first give an overview of the clinical trials with TRPV1 agonists (that “reignite the fire”) and then summarize the current state of the field pertaining to the known TRPV1 antagonists (“quenching the fire”) in clinical development. 


Available Options:
Version:
Special Focus Titles
01.Laryngeal Cancer: Risk Factors, Symptoms and Treatment
02.Breast Surgery: Indications and Techniques
03.Cursed? Biologic and Cultural Aspects of the Menstrual Cycle and Menstruation
04.The Uses of Cocoa and Cupuaçu Byproducts in Industry, Health, and Gastronomy
05.Agriculture, Food, and Food Security: Some Contemporary Global Issues
06.Fungicides: Perspectives, Resistance Management and Risk Assessment
07.Current Developments in Alexithymia - A Cognitive and Affective Deficit
08.Political Concerns and Literary Topoi in French Grand Opera
09.Abdul Aziz Said: The Mualim, The Inspiration
10.Teachers and Teaching: Global Practices, Challenges, and Prospects
11.A Comprehensive Investigation on Executive-Employee Pay Gap of Chinese Enterprises: Antecedents and Consequences
12.American Alligators: Habitats, Behaviors, and Threats

Nova Science Publishers
© Copyright 2004 - 2018

Targeting TRPV1 for Pain Relief: Should we Quench or Reignite the Fire?